Centrexion Therapeutics Announces CNTX-4975 Data Presentations at the 2019 American College of Rheumatology Annual Meeting an...
November 08 2019 - 8:00AM
Centrexion Therapeutics Corporation, a company focused on
developing non-opioid, non-addictive therapies for the treatment of
chronic pain, today announced it will present posters on CNTX-4975
at the 2019 American College of Rheumatology (ACR) Annual Meeting
Conference taking place November 8-13, 2019 in Atlanta, Georgia and
at the 2019 American Academy of Physical Medicine and
Rehabilitation (AAPM&R) Annual Assembly taking place November
14-17, 2019 in San Antonio, Texas.
Full abstracts are available online at acrabstracts.org. Details
of the poster presentation are listed below.
Title: Evaluation of Intra-articular CNTX-4975
in Subjects With Painful Bilateral Knee Osteoarthritis: Effects on
Pain With Walking and Patient Impression of Change in Pain
Session Title: Osteoarthritis – Clinical Poster I
Abstract Number: 1322Presentation
Time: Monday, November 11, 9:00AM –
11:00AMLocation: Georgia World Congress Center -
Hall B5
Full abstracts are available online at
eventscribe.com/2019/AAPMR. Details of the e-poster presentation
are listed below.
Title: Bilateral Intra-articular Injection of
CNTX-4975 for Management of Painful Osteoarthritis of the Knee:
Results at 6 Weeks From an Open-label TrialSession
Title: Musculoskeletal and Sports Medicine Research Report
Presentation Time: Thursday, November 14,
1:00PM – 1:05PMLocation: Research
Hub – Kiosk 8
About Osteoarthritis Osteoarthritis (OA) is the
most common joint disease in the U.S., currently affecting more
than 30 million Americans, according to the U.S. Centers for
Disease Control. OA occurs when cartilage, the tissue that envelops
the structural bones within a joint, gradually deteriorates. These
changes cause pain, swelling and problems moving the joint.
Although OA can affect any joint, it most often affects joints in
the knees, hips, lower back and neck, small joints of the fingers
and the bases of the thumb and big toe. Over time, patients with
knee OA tend to become inactive due to pain and joint stiffness and
reduced function.
About CNTX-4975 CNTX-4975, Centrexion’s most
advanced product candidate, is an investigational synthetic,
ultra-pure intra-articular injection of capsaicin for the treatment
of moderate-to-severe pain associated with knee OA. CNTX-4975 is
designed to be administered directly into the joint where the pain
stimulus originates and to selectively and locally target and
disrupt the signaling of pain-sensing nerve fibers. In January
2018, CNTX-4975 was granted Fast Track Designation by the U.S. Food
and Drug Administration for the treatment of moderate-to-severe
pain associated with knee OA.
About Centrexion Therapeutics Corporation
Centrexion is a late clinical-stage biopharmaceutical company
focused on becoming the leader in identifying, developing and
commercializing novel, non-opioid and nonaddictive therapies to
address the large unmet medical need for the treatment of chronic
pain.
Media Contact Julie Normart, W2O pure +1 (559)
974-3245 jnormart@w2ogroup.com
Investor Contact Courtney Dugan, W2O pure +1
(212) 257-6723 cdugan@w2ogroup.com
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Context Therapeutics (NASDAQ:CNTX)
Historical Stock Chart
From Jul 2023 to Jul 2024